ThromboGenics and VIB found oncology company

April 14, 2015 News BioVox


Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for the treatment of brain tumors in children. Alongside ThromboGenics, VIB (Flemish Institute for Biotechnology) will be a shareholder.

Medulloblastoma is a rare, but life-threatening, brain tumor that  occurs mostly in children. In this type of cancer, PLGF (placental growth factor) is (over-)expressed. TB-403 is a monoclonal antibody directed against PLGF. Animal studies were promising and the safety profile is favorable. TB-403 also has  potential as a treatment for other pediatric tumours. Johan Cardoen, executive at VIB, hopes to make Oncurious into a leading oncology company. 

Read more about this topic in our soon to be published Insights article.


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe

* indicates required

Intuit Mailchimp